|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002199,
umls-concept:C0005522,
umls-concept:C0005527,
umls-concept:C0006826,
umls-concept:C0007134,
umls-concept:C0016360,
umls-concept:C0021756,
umls-concept:C0022265,
umls-concept:C0035168,
umls-concept:C0087111,
umls-concept:C0205088,
umls-concept:C0282460,
umls-concept:C0443315,
umls-concept:C1257890,
umls-concept:C1274040
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2002-5-27
|
|
pubmed:abstractText |
The treatment of metastatic renal cell cancer remains unsatisfactory despite encouraging results with biotherapy. Pilot studies from other investigators have suggested that combining cis-retinoic acid and 5-fluorouracil (5FU) with interleukin-2 (IL-2) and interferon-alpha (IFN) may improve outcomes for such patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1084-9785
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
165-73
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12030110-Adult,
pubmed-meshheading:12030110-Aged,
pubmed-meshheading:12030110-Aged, 80 and over,
pubmed-meshheading:12030110-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12030110-Carcinoma, Renal Cell,
pubmed-meshheading:12030110-Female,
pubmed-meshheading:12030110-Fluorouracil,
pubmed-meshheading:12030110-Humans,
pubmed-meshheading:12030110-Injections, Subcutaneous,
pubmed-meshheading:12030110-Interferon-alpha,
pubmed-meshheading:12030110-Interleukin-2,
pubmed-meshheading:12030110-Kidney Neoplasms,
pubmed-meshheading:12030110-Male,
pubmed-meshheading:12030110-Middle Aged,
pubmed-meshheading:12030110-Recombinant Proteins,
pubmed-meshheading:12030110-Survival Rate,
pubmed-meshheading:12030110-Treatment Outcome,
pubmed-meshheading:12030110-Tretinoin
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
|
|
pubmed:affiliation |
Alegent Bergan Mercy Medical Center, Omaha, NB, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
